NeuroSense Therapeutics L... (NRSN)
0.99
-0.01 (-1.00%)
At close: Apr 22, 2025, 11:34 AM
-1.00% (1D)
| Bid | 0.99 |
| Market Cap | 23.86M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.21M |
| EPS (ttm) | -0.54 |
| PE Ratio (ttm) | -1.84 |
| Forward PE | -1.88 |
| Analyst | n/a |
| Ask | 1 |
| Volume | 13,384 |
| Avg. Volume (20D) | 152,749 |
| Open | 1.01 |
| Previous Close | 1.00 |
| Day's Range | 0.99 - 1.01 |
| 52-Week Range | 0.51 - 1.50 |
| Beta | 1.34 |
About NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 9, 2021
Employees 17
Stock Exchange NASDAQ
Ticker Symbol NRSN
Website https://www.neurosense-tx.com
4 months ago
+12.28%
NeuroSense Therapeutics shares are trading higher....
Unlock content with
Pro Subscription
4 months ago
+14.27%
NeuroSense Therapeutics shares are trading higher after the company announced its CEO purchased $5 million worth of ordinary shares in a private placement.
